Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

T1200000

Thiopental

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(±)-Thiopental, 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid, Pentothal

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H18N2O2S
CAS Number:
76-75-5
Molecular Weight:
242.34
MDL number:
MFCD00057564
UNSPSC Code:
41116107
PubChem Substance ID:
329826660
Pricing and availability is not currently available.

API family

thiopental

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

CCCC(C)C1(CC)C(=O)NC(=S)NC1=O

InChI

1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)

InChI key

IUJDSEJGGMCXSG-UHFFFAOYSA-N

Gene Information

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Thiopental EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P301 + P312 + P330

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Colleen K Loo et al.
Journal of affective disorders, 142(1-3), 233-240 (2012-08-04)
Preliminary evidence suggests that the use of ketamine during electroconvulsive therapy (ECT) may be neuroprotective against cognitive impairment and have synergistic antidepressant effects. This study tested whether the addition of ketamine reduced cognitive impairment and enhanced efficacy over a course
H Murdoch et al.
International journal of obstetric anesthesia, 22(1), 31-35 (2012-11-06)
A national survey of current practice and preferred drug choices for both induction and maintenance of general anaesthesia for caesarean section was undertaken. Following approval by the Obstetric Anaesthetists' Association, all UK consultant members were invited to respond to an
Elisabeth Norman et al.
Pediatric research, 73(1), 87-94 (2012-11-07)
Sedative and analgesic medications are used in critically ill newborns, but little is known about their effects on electrocortical activity in preterm infants. We hypothesized that morphine might induce prolonged neurodepression, independent of blood pressure, as compared with rapid sequence
Anna Rosati et al.
Neurology, 79(24), 2355-2358 (2012-12-01)
To evaluate the efficacy and safety of ketamine (KE) in the management of refractory convulsive status epilepticus (RSE) in children. In November 2009, we started using KE for treating all children consecutively referred for RSE. Clinical and treatment data were
Chadi G Abdallah et al.
The journal of ECT, 28(3), 157-161 (2012-08-01)
Studies now provide strong evidence that the N-methyl-D-aspartate receptor antagonist ketamine possesses rapidly acting antidepressant properties. This study aimed to determine if a low dose of ketamine could be used to expedite and augment the antidepressant effects of electroconvulsive therapy
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service